| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 2 securities · passive | ||||||
|
Ernexa Therapeutics Inc.
13G/A
ERNA · 114082407
|
5.6% |
5/15/2026
Event 2/10/2026
|
||||
| John D. Halpern | 5.6% | |||||
| Katherine H. Halpern | 5.6% | |||||
|
Eterna Therapeutics Inc.
13G/A
ERNA · 114082209
|
9.6% |
5/15/2025
Event 3/31/2025
|
||||
| John D. Halpern | 9.6% | |||||
| Katherine H. Halpern | 9.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.